
- Pharmaceutical Technology-05-02-2019
- Volume 43
- Issue 5
New Kit Identifies Endonuclease Impurities
The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy.
The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy. With a detection limit of ~0.06 ng/mL, the kit is three times more sensitive than the only other commercially available assay for detection and quantitation of these endonuclease impurities, according to the company. The kit also contains all the necessary, ready-to-use reagents for 96 analyses in microplate format, including a set of calibrated endonuclease standards. The assay can be easily integrated into desired workflow points-from process development to quality control to lot release testing.
Articles in this issue
over 6 years ago
Closed Systems for Aseptic Fill and Finishover 6 years ago
Contract Packaging Growsover 6 years ago
New Pneumatic Pressesover 6 years ago
New Size for AODD Pumpover 6 years ago
1000-Gallon Pivoting Triple Shaft Mixerover 6 years ago
Bioprocessing Facilities and FDA Inspection Problemsover 6 years ago
FDA Faces Challenges After Gottliebover 6 years ago
The Auditor Vs. Inspector Issueover 6 years ago
Avoiding Excipient Variabilityover 6 years ago
Working for the Greater GoodNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


